The Phase II results of the NRG Oncology HN004 trial indicate that radiotherapy (RT) with the PD-L1 inhibitor durvalumab did not improve progression-free survival (PFS) and led to significantly higher rates of locoregional ...
Oct 24, 2022
0
6
Almost all liver cancers develop after decades of chronic liver disease, but a new discovery by Columbia researchers may lead to treatments that could break the link.
Oct 21, 2022
0
478
A breast cancer diagnosis can take you down a path of deeply personal choices. If you are having a mastectomy (the removal of one or both breasts), you'll likely have questions about the type of reconstruction to have—if ...
Oct 20, 2022
0
2
Among patients with kidney cancer, the activity of four specific genes in the cancer cells seems to be able to predict the risk of the tumor spreading and the patient's chances of survival. This is shown by researchers from ...
Oct 17, 2022
0
66
Alcohol consumption and hepatitis C viral infection are known risk factors for causing hepatocellular carcinoma, the most common form of liver cancer. Apart from these, obesity-associated nonalcoholic fatty liver disease ...
Oct 17, 2022
0
49
Scientists have solved a long-standing mystery surrounding a cancer-promoting protein and how it causes tumor growth. The findings are an important step in the quest to make cancer drugs more effective since aggressive tumors ...
Oct 12, 2022
0
14
October is Breast Cancer Awareness Month, which makes this a good time to learn about breast cancer types and what your type means.
Oct 5, 2022
0
29
The ancient Egyptians, as described in the Ebers Papyrus, already knew that palpation—feeling for hardened lumps—can help diagnose breast cancer. Palpation is still an important element in early screening for breast cancer. ...
Sep 30, 2022
0
61
Medicine has advanced dramatically during the last century. But when it comes to getting biopsy results, very little has changed. Consider, for example, what happens when a patient comes in to have a skin lesion biopsied ...
Sep 27, 2022
0
73
Disease-free survival (DFS) does not differ with adjuvant nivolumab plus ipilimumab (NIVO+IPI) compared with placebo in patients with localized renal cell carcinoma (RCC) at high risk for postnephrectomy relapse, according ...
Sep 14, 2022
0
9
